Patients with anorexia have elevated levels of CB1 receptors in brains. Similarly, bulimia patients were also shown to have elevated levels of CB1 receptors in some brain regions (Gérard et al., 2011).
It was demonstrated that mutations in CB1 and FAAH (the major endocannabinoid degrading enzyme) are connected to anorexia and bulimia (Monteleone et al., 2009).
2AG and AEA play a role in controlling food intake (Fride, Bregman, & Kirkham, 2005).
Hyperphagia (excessive or extreme hunger) caused by CBG in animals does not produce negative neuromotor side effects (Brierley, Samuels, Duncan, Whalley, & Williams, 2016).
Likewise, CBG-BDS can help stimulate appetite, probably via CB1 (Brierley, Samuels, Duncan, Whalley, & Williams, 2017).